Laboratorios de Biológicos y Reactivos de Mexico, S.A. de C.V., Birmex, Amores 1240, Col. del Valle, Mexico D.F., C.P. 03100, Mexico.
Vaccine. 2011 Jul 1;29 Suppl 1:A26-8. doi: 10.1016/j.vaccine.2011.04.121.
The Mexican Government developed a plan in 2004 for pandemic influenza preparedness that included local production of influenza vaccine. To achieve this, an agreement was concluded between Birmex - a state-owned vaccine manufacturer - and sanofi pasteur, a leading developer of vaccine technology. Under this agreement, sanofi pasteur will establish a facility in Mexico to produce antigen for up to 30 million doses of egg-based seasonal vaccine per year, and Birmex will build a facility to formulate, fill and package the inactivated split-virion influenza vaccine. As at November 2010, the sanofi pasteur facility has been completed and the Birmex plant is under construction. Most of the critical equipment has been purchased and is in the process of validation. In addition to intensive support from sanofi pasteur for the transfer of the technology, the project is supported by the Mexican Ministry of Health, complemented by Birmex's own budget and grants from the WHO developing country influenza technology transfer project.
墨西哥政府于 2004 年制定了一项大流行性流感防范计划，其中包括本国生产流感疫苗。为实现这一目标，Birmex（一家国有疫苗制造商）与疫苗技术领先开发商赛诺菲巴斯德签署了一项协议。根据该协议，赛诺菲巴斯德将在墨西哥建立一个生产抗原的设施，每年生产多达 3000 万剂基于鸡蛋的季节性疫苗，Birmex 将建立一个生产、填充和包装流感灭活裂解病毒疫苗的设施。截至 2010 年 11 月，赛诺菲巴斯德的设施已经完工，Birmex 的工厂正在建设中。大部分关键设备已经采购，并正在进行验证。除了赛诺菲巴斯德在技术转让方面的大力支持外，该项目还得到了墨西哥卫生部的支持，Birmex 自身的预算以及世卫组织发展中国家流感技术转让项目也提供了补充资金。
